DE60021098D1 - Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung - Google Patents

Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung

Info

Publication number
DE60021098D1
DE60021098D1 DE60021098T DE60021098T DE60021098D1 DE 60021098 D1 DE60021098 D1 DE 60021098D1 DE 60021098 T DE60021098 T DE 60021098T DE 60021098 T DE60021098 T DE 60021098T DE 60021098 D1 DE60021098 D1 DE 60021098D1
Authority
DE
Germany
Prior art keywords
production
resin
isoagglutinine
regeneration
free blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60021098T
Other languages
English (en)
Other versions
DE60021098T2 (de
Inventor
N Chin
J Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VI Technologies Inc
Original Assignee
VI Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23647483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60021098(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by VI Technologies Inc filed Critical VI Technologies Inc
Application granted granted Critical
Publication of DE60021098D1 publication Critical patent/DE60021098D1/de
Publication of DE60021098T2 publication Critical patent/DE60021098T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/203—Equilibration or regeneration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
DE60021098T 1999-10-08 2000-10-06 Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung Revoked DE60021098T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41585499A 1999-10-08 1999-10-08
PCT/US2000/027711 WO2001027623A2 (en) 1999-10-08 2000-10-06 Isoagglutinin-depleted blood compositions and methods of making same

Publications (2)

Publication Number Publication Date
DE60021098D1 true DE60021098D1 (de) 2005-08-04
DE60021098T2 DE60021098T2 (de) 2006-06-14

Family

ID=23647483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021098T Revoked DE60021098T2 (de) 1999-10-08 2000-10-06 Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung

Country Status (9)

Country Link
EP (1) EP1224462B1 (de)
JP (1) JP2003511468A (de)
AT (1) ATE298889T1 (de)
AU (1) AU1074601A (de)
CA (1) CA2385179A1 (de)
DE (1) DE60021098T2 (de)
ES (1) ES2240187T3 (de)
MX (1) MXPA02003517A (de)
WO (1) WO2001027623A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803315B2 (en) * 2001-10-05 2010-09-28 American Sterilizer Company Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents
US7001873B2 (en) * 2001-10-05 2006-02-21 Steris Inc. Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
JP5274771B2 (ja) * 2003-04-08 2013-08-28 ノヴォ ノルディスク アー／エス クロマトグラフィー固定相の再生
EP1506809A1 (de) * 2003-08-11 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co. KG Regenerierung von hydrolyseempfindlichen Adsorptionsmatrizen
EP1506810A1 (de) * 2003-08-11 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Regenerierung von hydrolyseempfindlichen Adsorptionsmatrizen
DE102004009400A1 (de) 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
EP1885488B1 (de) * 2005-05-24 2015-07-08 GE Healthcare Bio-Sciences AB Regeneration einer chromatographiematrix
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
US9102709B1 (en) * 2011-07-08 2015-08-11 Biogen Ma Inc. Regeneration of chromatography material
BE1021755B1 (fr) 2012-09-26 2016-01-15 Bone Therapeutics S.A. Formulations comporenant du plasma traite par solvant/detergent (plasma s/d) et utilisations de celles-ci
FR3026950A1 (fr) * 2014-10-09 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de plasma universel
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
FR3035971A1 (fr) 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b
FR3035789A1 (fr) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies
US10697983B2 (en) * 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies
US20170066839A1 (en) * 2015-09-08 2017-03-09 Merck Patent Gmbh Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies
US10697982B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies
EP3254671B1 (de) 2016-06-10 2019-11-13 Octapharma AG Hochkonzentrierte immunglobulinzusammensetzung zur pharmazeutischen anwendung
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
EP3573734A1 (de) * 2017-01-30 2019-12-04 Regeneron Pharmaceuticals, Inc. Verfahren zur verringerung von biobelastung in der chromatografie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664913A (en) * 1982-05-24 1987-05-12 Xoma Corporation Method for treating plasma for transfusion
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors

Also Published As

Publication number Publication date
JP2003511468A (ja) 2003-03-25
EP1224462B1 (de) 2005-06-29
WO2001027623A3 (en) 2002-01-17
ES2240187T3 (es) 2005-10-16
ATE298889T1 (de) 2005-07-15
DE60021098T2 (de) 2006-06-14
EP1224462A2 (de) 2002-07-24
AU1074601A (en) 2001-04-23
WO2001027623A2 (en) 2001-04-19
CA2385179A1 (en) 2001-04-19
MXPA02003517A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
DE60021098T2 (de) Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung
ATE402753T1 (de) Reinigung von ionischen flüssigkeiten
DE69929986D1 (de) Verfahren zur entfernung von hiv und anderen viren aus blut
IL228277A (en) METHOD FOR INVESTIGATING THE SAFETY SAFETY OF ANTICIPATIVES VIII IN VIEW CONTENTS
ATE364060T1 (de) Mikroporöse materialien und verfahren zu ihrer herstellung
DE69737294D1 (de) Verfahren zur abtrennung des alpha-1-proteinase inhibitors von einer cohn-paste, welche die fraktionen iv-1 + iv-4 enthält
DE69913320D1 (de) Verfahren zur behandlung von gas-strömen bei der polyolefinherstellung
DE60221838D1 (de) Verfahren zur herstellung von aufgeschäumten polypropylenharzteilchen
ATE517180T1 (de) Verwendung von esterasen zur spaltung von kunststoffen
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
ATE432946T1 (de) Abtrennung von fibrinogen von plasmaproteasen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
ATE497517T1 (de) Verfahren zur trennung von polyester von anderen materialien
DE59814369D1 (de) Filtrationsverfahren zur trennung von viren
DE69801548T2 (de) Verfahren zur Reinigung von 1,4-Butandiol durch Schmelzkristallisation
DE502004008678D1 (de) Verfahren zur Herstellung von gereinigten Elastomeren aus Lösung
DE60237649D1 (de) Flüssigkeitsfiltrierverfahren
DE50311487D1 (de) Verfahren zur Herstellung von Kompositmembranen
DK1101735T3 (da) Fremgangsmåde til fjernelse af skabelonmidlet fra syntetiske zeolitter
DE60216931D1 (de) Verfahren zur herstellung von bisphenol-a
DE50006245D1 (de) Verfahren zur herstellung von (1,1':4',1'')-terphenylvebindungen
BRPI0408899A (pt) compostos benzo[1,2,5]tiadiazol
Burnouf Current status and new developments in the production of plasma derivatives
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid
DE60333077D1 (de) Neues verfahren zur herstellung von 1,2-diol

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent
8331 Complete revocation